Expand all sections

Aflibercept

Zaltrap

Extended indication Diabetic macular edema
Therapeutic value Possible equal value
Registration phase Registration application pending

Product

Active substance Aflibercept
Domain Neurological disorders
Reason of inclusion Biosimilar
Main indication Eye disorders
Extended indication Diabetic macular edema
Current proprietary name Eylea (Bayer)
Proprietary name Zaltrap
Manufacturer Sanofi
Mechanism of action Angiogenesis inhibitor
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Submission date May 2022
Expected Registration May 2023
Orphan drug No
Registration phase Registration application pending
Additional remarks SPC Eylea verloopt op 22 mei 2025.

Therapeutic value

Therapeutic value Possible equal value

Expected patient volume per year

Patiëntvolume is niet van toepassing bij generieke geneesmiddelen of biosimilars.

Expected cost per patient per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

Potential total cost per year

Horizonscan vermeldt geen prijsinformatie van generieke geneesmiddelen of biosimilars om het eventueel beïnvloeden van de markt te voorkomen.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.